In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, highlights how the MMRF accelerates trial timelines for biopharmas by integrating an adaptive platform model.
In a recent video interview with Applied Clinical Trials, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation (MMRF), discussed challenges in multiple myeloma clinical trials, including inefficiency, lack of focus on critical patient questions, and underrepresentation of diverse patient populations. Andreini also highlighted the Horizon clinical trial and how MMRF is working to address unmet need in the myeloma research space.
ACT: How is MMRF helping biopharma companies evaluate their multiple myeloma therapies in trials they wouldn’t run on their own?
Andreini: I'll give you a concrete example here, so our first biopharma partner in our Horizon clinical trials program is Johnson & Johnson, and we're helping them to determine what is the optimal dosing strategy for a drug called teclistamab to maximize efficacy and limit safety and tolerability concerns. This is an incredibly important question for Johnson & Johnson to answer, and it's also an important question for patients who will be treated with this therapy, so J&J could conduct this type of trial on their own, but it would take much longer, and would cost them much more than it will cost us because of this adaptive platform model that we've put into place and our consortium of research partners that we have in place, where we have pre-negotiated contracts with all of these sites, so it's a much more efficient process overall. What's attractive about it to J&J and other biopharma partners is that it allows them to more rapidly generate robust randomized control data to support again, answering the question of optimal use of their therapy than they could do otherwise.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
What Can ClinOps Learn from Pre-Clinical?
August 10th 2021Dr. Hanne Bak, Senior Vice President of Preclinical Manufacturing and Process Development at Regeneron speaks about her role at the company as well as their work with monoclonal antibodies, the regulatory side of manufacturing, and more.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.